Melanoma News

The daily melanoma news is a unique cancer news service that evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and health care providers. The daily cancer news provides information about emerging options for melanoma prevention, early detection and melanoma treatment, as well as advances in supportive care and personalized medicine. Supportive care improves quality of life by making melanoma treatment more tolerable, and personalized medicine offers the potential for improved treatment outcomes by using specific characteristics of the patient or the cancer to guide cancer treatment decisions. In addition, interested individuals can search the Cancer Consultants Melanoma News Archives to find the results of the cancer studies that led to the care they have been offered.

Share

Melanoma News


Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying... Continue Reading

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients... Continue Reading

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National... Continue Reading

Combined Targeted Therapy Safe and Effective in Metastatic Melanoma (October 24, 2012)

Treatment with a combination of two targeted agents—dabrafenib, which targets BRAF, and trametinib, which targets MEK—in patients with metastatic melanoma and BRAF V600 mutations was safe and improved... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship... Continue Reading

New Targeted Therapies Show Promise in Advanced Melanoma (June 18, 2012)

Two new targeted therapies—trametinib and dabrafenib—show promise in the treatment of advanced melanoma, either improving survival or delaying disease progression, according to the results of two studies... Continue Reading

PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the risk. Of the more than one million new diagnoses of... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

NSAIDs Might Reduce Risk of Skin Cancer (June 4, 2012)

The use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen may reduce the risk of developing skin cancer, according to a recent study published in the journal Cancer.[1] Skin cancer is the most commonly diagnosed cancer in... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening and Prevention

Stages I-II

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

Women More Likely to Survive Melanoma Than Men (May 16, 2012)

Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading

Sentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck (August 10, 2011)

Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin cancer is the most commonly diagnosed cancer in the... Continue Reading

Wealthy Women at Higher Risk of Melanoma (April 6, 2011)

It appears that wealthier White women may be at a higher risk of melanoma than less affluent women. These findings were recently published in the Archives of Dermatology. Melanoma is the most deadly type of skin cancer. Each year in the United States,... Continue Reading

More Stages I-II

Stage III

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

New Targeted Therapies Show Promise in Advanced Melanoma (June 18, 2012)

Two new targeted therapies—trametinib and dabrafenib—show promise in the treatment of advanced melanoma, either improving survival or delaying disease progression, according to the results of two studies presented at the 2012 annual meeting of the... Continue Reading

Melanoma Drug Accelerates Secondary Skin Cancers In Some Patients (January 23, 2012)

Zelboraf® (vemurafenib) improves outcomes among patients with advanced melanoma that harbors a BRAF gene mutation, but also accelerates the development of squamous cell carcinoma in some patients. A study that explores the reasons for these secondary... Continue Reading

Zelboraf (Vemurafenib) Approved for Melanoma (August 22, 2011)

The targeted therapy Zelboraf™ (vemurafenib) has been approved by the US Food and Drug Administration (FDA) for the treatment of melanomas that carry a common mutation in the BRAF gene. Of the more than one million new diagnoses of skin cancer each... Continue Reading

Sentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck (August 10, 2011)

Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin cancer is the most commonly diagnosed cancer in the... Continue Reading

More Stage III

Stage IV

Combined Targeted Therapy Safe and Effective in Metastatic Melanoma (October 24, 2012)

Treatment with a combination of two targeted agents—dabrafenib, which targets BRAF, and trametinib, which targets MEK—in patients with metastatic melanoma and BRAF V600 mutations was safe and improved progression-free survival, according to the results... Continue Reading

Factors Affecting Quality of Life at the End of Life (July 20, 2012)

For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance with their physicians, according to the results of... Continue Reading

New Targeted Therapies Show Promise in Advanced Melanoma (June 18, 2012)

Two new targeted therapies—trametinib and dabrafenib—show promise in the treatment of advanced melanoma, either improving survival or delaying disease progression, according to the results of two studies presented at the 2012 annual meeting of the... Continue Reading

PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase I study presented at the 2012 annual meeting... Continue Reading

Zelboraf Improves Melanoma Survival (March 16, 2012)

Among patients with previously treated metastatic melanoma that carries a certain gene mutation, the targeted drug Zelboraf® (vemurafenib) resulted in a median overall survival of 16 months. This is a substantial improvement over what has been seen in... Continue Reading

More Stage IV

Recurrent

Combined Targeted Therapy Safe and Effective in Metastatic Melanoma (October 24, 2012)

Treatment with a combination of two targeted agents—dabrafenib, which targets BRAF, and trametinib, which targets MEK—in patients with metastatic melanoma and BRAF V600 mutations was safe and improved progression-free survival, according to the results... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase I study presented at the 2012 annual meeting... Continue Reading

Zelboraf Improves Melanoma Survival (March 16, 2012)

Among patients with previously treated metastatic melanoma that carries a certain gene mutation, the targeted drug Zelboraf® (vemurafenib) resulted in a median overall survival of 16 months. This is a substantial improvement over what has been seen in... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

More Recurrent

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS